Google DeepMind launches AlphaGenome 2, trained on 100M+ cell profiles across 68 tissues to predict genetic mutation effects, for non-commercial research (Robert Hart/The Verge)

More in Artificial Intelligence

• Tel Aviv- and SF-based Edelbyte, which is building a data analytics platform optimized for AI agents, emerges from stealth with $70M across Series A and seed (Tim Keary/Forbes)

  The cross-border startup is targeting the growing enterprise ecosystem by designing specialized analytics infrastructure tailored to autonomous digital software. This substantial launch capital allows the team to scale development across its dual headquarters in Israel and California. The move signals heightened investor appetite for back-end data architectures built expressly to serve next-generation artificial intelligence workflows.

  1 min read
• STAT+: Why this former ER doc thinks giving AI less information is sometimes better

  Healthcare technology developers are increasingly pushing to ingest extensive patient records and administrative files to power broader clinical recommendations. This rapid transition from narrow, single-purpose functions to wide-ranging medical decision support challenges traditional clinical perspectives on data limitation. The shift marks an aggressive effort by digital health platforms to expand their operational footprints across patient care.

  1 min read
• 'Cancer will be history in 10 years': Anthropic CEO's big AI-powered promise

  To accelerate therapeutic development, Anthropic has forged partnerships with pharmaceutical companies and biotechs like Bristol Myers Squibb and BigHat Biosciences. The initiatives leverage the company's Claude AI models to engineer treatments for rare diseases, food allergies, and various forms of cancer. While laboratory tests show promise in optimizing drug molecules, the technologies remain strictly in preclinical development phases.

  1 min read